Treatment
Pembrolizumab
4
Conditions
1,183
Trials
80K
Participants
38%
Average Safety
Condition Evidence
Cervical cancer
457 trials · 3,000 participants
45% effectiveness · 40% safety
Malignant skin melanoma
65 trials · 12K participants
88% effectiveness · 35% safety
Stomach cancer
161 trials · 15K participants
70% effectiveness · 40% safety
Tracheal, bronchus, and lung cancer
500 trials · 50K participants
85% effectiveness · 35% safety